12 Best Small-Cap Dividend Stocks To Buy

6. John Wiley & Sons, Inc. (NYSE:WLY)

Number of Hedge Fund Holders: 23

Dividend Yield as of December 5: 4.38%

Market Cap as of December 5: $1.724B

John Wiley & Sons, Inc. (NYSE:WLY) is one of the best dividend stocks to buy. On November 25, WLY disclosed that it has entered a partnership with IQVIA Holdings Inc. (NYSE:IQV) to provide a trusted solution to enforce the Clinical Outcome Assessment (COA) execution.

Through this partnership, COA instruments are easily available to pharmaceutical and research organizations. This one-stop solution makes the COA process easier, easing vendor-related workflows, providing quality assurance, and guaranteeing that the COA implementation aligns with scientific guidance.

Normally, COA licensing involves multiple vendors, including publishers for instrument licenses, language translation services, and implementation consultants. This is a lengthy process, taking months in some cases, which halts trial timelines and can potentially cause issues in quality assurance or compliance. This partnership between Wiley and IQVIA simplifies the process by providing a combined COA licensing and implementation solution in one contract. It is overseen by a rightsholder that endorses scientific accuracy and protects copyrights.

Phase one has five Wiley-managed COA tools offered as complete solutions, and the plan is to expand this to Wiley’s broader lineup of more than 100 COAs, along with full lifecycle services, by the end of 2026. These instruments assist in clinical research for specialized fields, including anxiety and depression, pediatric cancer functional status, lupus-related organ damage, and physical sexual maturity review.

In collaboration with IQVIA, John Wiley & Sons, Inc. (NYSE:WLY) provides qualified instruments with in-built support for translation, digital migration, and implementation within a singular integrated solution. This collaboration indicates Wiley’s expertise in integrating dependable research resources into clinical platforms that serve pharmaceutical and biotech companies.

John Wiley & Sons, Inc. (NYSE:WLY) is a New Jersey-based publisher that offers reliable content, data insights, and learning services across the United States and internationally.